Olympus to develop Kaken's growth factor in the US and Europe
This article was originally published in Scrip
Executive Summary
Kaken has licensed its human basic fibroblast growth factor (bFGF) product trafermin to the diversified Japanese group Olympus, for development, manufacture and marketing in wound healing applications in North America and Europe.